Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.
| Revenue (TTM) | $1.66B |
| Gross Profit (TTM) | $1.27B |
| EBITDA | $1.05B |
| Operating Margin | 59.80% |
| Return on Equity | 173.70% |
| Return on Assets | 25.50% |
| Revenue/Share (TTM) | $14.15 |
| Book Value | $1.26 |
| Price-to-Book | 88.91 |
| Price-to-Sales (TTM) | 8.31 |
| EV/Revenue | 8.82 |
| EV/EBITDA | 15.89 |
| Quarterly Earnings Growth (YoY) | 42.90% |
| Quarterly Revenue Growth (YoY) | 47.70% |
| Shares Outstanding | $113.50M |
| Float | $112.19M |
| % Insiders | 1.08% |
| % Institutions | 113.53% |
Volatility is currently expanding
HALO, GCT, LIND, PR and CVX stand out as relative strength picks amid market volatility, backed by strong price performance and upbeat earnings estimates.
ROST, ROKU, APA, CORT and HALO are five non-tech Nasdaq stocks riding strong growth trends and rising earnings estimates, positioning them for potential gains in Q4.
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Halozyme wins a Dutch court order blocking Merck's Keytruda SC in eight European markets, strengthening its position in the patent dispute.
Halozyme expands its ENHANZE pact with argenx to eight targets, opening the door to new milestones and royalties as revenue growth accelerates.
SAN DIEGO, Oct. 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") announced today that the specialized Dutch patent court of the Hague has found Merck to be infringing one of its MDASE patents, EP 2,797,622 (EP622) and ordered Merck's central European Market Authorization Holder and worldwide packaging and distribution hub MSD BV to refrain from manufacturing, having manufactured, offering, placing on the market and using, or importing or stocking for these purposes, Keytruda SC in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands. The injunction also forbids MSD to facilitate infringement by its affiliates, including by allowing the use of its European Marketing Authorization.
Expanded agreement increases argenx's exclusive access to ENHANZE® from six to eight targets SAN DIEGO, Oct. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced that it has expanded its global collaboration and license agreement with argenx to develop and commercialize ENHANZE® with two additional exclusive targets. "We are pleased to expand our collaboration with argenx, a recognized leader in immunology, building on the successful development of VYVGART Hytrulo," said Dr. Helen Torley, President and Chief Executive Officer of Halozyme.
SAN DIEGO, Sept. 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of James "Jim" Daly to its Board of Directors.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HALO and any ticker you trade — then tracks every position and per-strategy win rate.
